People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pacific Diabetes Technologies, Inc. | — | Biotechnology | Seed | $9.0M | $8.1M | 2025 |
Thomas Seidl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Seidl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher Marsh | 1 | 4 |
| Mark Huber | 1 | 3 |
| Kenneth Ward | 1 | 2 |
| Ken Ward | 1 | 2 |
| Edward La Cava | 1 | 1 |
| Thomas Seidel | 1 | 1 |
| Yobie Benjamin | 1 | 1 |
| Hank Wuh | 1 | 1 |
| Peter Eckenberg | 1 | 1 |
| Ed La Cava | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.